Adverse events associated with benznidazole treatment for Chagas disease in children and adults
Although 29.34% of patients experienced ADRs, most were mild to moderate, indicating a manageable safety profile for benznidazole. While optimized dosing schedules and new drugs are needed, avoiding benznidazole solely due to safety concerns is not justified.
Authors
- Jaime Altcheh (ORCID: https://orcid.org/0000-0002-5865-7991)
- Facundo García‐Bournissen (ORCID: https://orcid.org/0000-0002-8732-247X)
- Guillermo Moscatelli (ORCID: https://orcid.org/0000-0002-6986-4646)
- Samanta Moroni (ORCID: https://orcid.org/0000-0003-4034-2876)
- Andrés Rabinovich (ORCID: https://orcid.org/0000-0002-9291-9078)
- Cintia Cruz (ORCID: https://orcid.org/0000-0001-8393-8536)
- Nicolás González (ORCID: https://orcid.org/0000-0001-7116-1002)
- Griselda Ballering (ORCID: https://orcid.org/0000-0002-8749-1249)
- Héctor Freilij
Institutions
- Western University (CA)
- Consejo Nacional de Investigaciones Científicas y Técnicas (AR)
- University of Oxford (GB)
- Hospital General de Niños Ricardo Gutierrez (AR)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1111/bcp.16214
- Citations
- 6
- Primary Topic
- Trypanosoma species research and implications
- Type
- article
- Field-Weighted Citation Impact
- 2.32
Funders
- Wellcome Trust